Business
DECN Says its Newest GenViro! COVID-19 Swift Kit Saliva Testing Option Can Play an Extensive Role in the Re-Opening of Schools as Company Awaits FDA Authorization
DECN Says its Newest GenViro! COVID-19 Swift Kit Saliva Testing Option Can Play an Extensive Role in the Re-Opening of Schools as Company Awaits FDA Authorization.
About this update from Decision Diagnostics Corp
[{"type":"text","content":""Designed to be swift, safe, non-invasive, and accurate, GenViro! Saliva Based Swift Kit planned to help send students of all ages back to school"LOS ANGELES, CA / ACCESSWIRE / July 17, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc., today stated that the country does have the know-how and means to provide, "swift, safe, non-invasive and accurate testing methodology to help send our kids back to school." DECN has been a provider of diabetic testing products for almost two decades. Diabetic glucose test strips are a safe and effective technology used by millions of diabetics around the globe for years. The company's patent pending impedance based technology is used on all of its Covid-19 Swift Kit test kits. DECN's Pharma Tech Solutions subsidiary currently has two applications for FDA EUA authorization of its GenViro! blood testing kits to detect the Covid-19 virus. More recently, DECN announced it is testing and will be filing another EUA for its non-invasive saliva testing kits using the same technology consisting of testing strips and slightly modified meter software as its Covid-19 blood test kits. Both forms of test kits could help all schools, from elementary to the university level, open more safely, as well as offer testing at the point of care for the students and the adults working in these institutions. Recent tests completed on both the whole blood and saliva methodologies show an almost identical testing profile (see below).The company has been conducting its testing efforts overseas while actively seeking FDA approval for testing protocols in the U.S. DECN's Pharma Tech Solutions subsidiary first submitted its proposed GenViro! professional use device to the FDA on April 3, 2020. The request for a saliva based method came to the company directly from its international distributor. Now DECN believes that there are many other uses for the saliva based kit, "back to school" being a current most important use.The company plans to provide the new single use saliva testing kit option to its professional and individual use finger stick GenViro! Covid 19 Swift Kit test kits designed to identify Covid-19 viral load. Test reporting for the GenViro! finger stick kits are currently producing results at :10.5 seconds, and initial tes...